• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 Cloudz 微球、G-Rex6M 和人血小板裂解物无饲养细胞和无血清扩增自然杀伤细胞。

Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate.

机构信息

Bio-Techne, Woburn, MA, United States.

出版信息

Front Immunol. 2022 Mar 7;13:803380. doi: 10.3389/fimmu.2022.803380. eCollection 2022.

DOI:10.3389/fimmu.2022.803380
PMID:35320938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8934851/
Abstract

The versatility of natural killer cells has ignited growing interest in their therapeutic use for cancer and other immunotherapy treatments. However, NK cells compose a small portion of peripheral blood mononuclear cells (5%-20% of PBMCs) and clinical doses require billions of cells. Manufacturing suitable doses of NK cells remains a major challenge for NK immunotherapy. The current standard for expanding NK cells relies on feeder cells and fetal bovine serum to achieve large expansion, but both encounter regulatory concerns. We developed NK Cloudz, a dissolvable polymer-based microsphere platform, as an alternative to a feeder cell approach to expand NK cells. We demonstrated that a combination of NK Cloudz, a G-Rex6M culture vessel, and GMP Human Platelet Lysate expanded NK cells 387 ± 100-fold in 10 days from a PBMC starting population. The NK purity, viability, and cytotoxicity were similar to both a feeder cell protocol and an FBS-based protocol. Additionally, we found no significant differences between FBS and GMP Human Platelet Lysate and concluded that platelet lysate is a good xeno-free alternative to FBS for NK expansion. Overall, we demonstrated a feeder-cell-free and FBS-free protocol that leverages NK Cloudz as a promising step toward a commercial GMP manufacturing method to expand NK cells for therapeutic use.

摘要

自然杀伤细胞的多功能性激发了人们对其在癌症和其他免疫疗法治疗中的治疗用途的浓厚兴趣。然而,NK 细胞在周围血单核细胞(PBMC)中仅占很小一部分(占 PBMC 的 5%-20%),而临床剂量需要数十亿个细胞。制造合适剂量的 NK 细胞仍然是 NK 免疫疗法的主要挑战。目前扩增 NK 细胞的标准依赖于饲养细胞和胎牛血清来实现大规模扩增,但这两者都存在监管方面的问题。我们开发了 NK Cloudz,这是一种基于可溶解聚合物的微球平台,可作为替代饲养细胞的方法来扩增 NK 细胞。我们证明,NK Cloudz 与 G-Rex6M 培养容器和 GMP 人血小板裂解物的组合可在 10 天内将 PBMC 起始群体扩增 387 ± 100 倍。NK 细胞的纯度、活力和细胞毒性与饲养细胞方案和基于 FBS 的方案相似。此外,我们发现 FBS 和 GMP 人血小板裂解物之间没有显著差异,并得出结论,血小板裂解物是替代 FBS 用于 NK 扩增的无动物源替代品。总体而言,我们展示了一种无饲养细胞和无 FBS 的方案,该方案利用 NK Cloudz 作为一种有前途的方法,朝着用于治疗用途的商业 GMP 制造方法来扩大 NK 细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/d916429182de/fimmu-13-803380-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/02b8ee313d59/fimmu-13-803380-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/e3904c724675/fimmu-13-803380-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/017dd22339f4/fimmu-13-803380-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/d916429182de/fimmu-13-803380-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/02b8ee313d59/fimmu-13-803380-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/e3904c724675/fimmu-13-803380-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/017dd22339f4/fimmu-13-803380-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/8934851/d916429182de/fimmu-13-803380-g004.jpg

相似文献

1
Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate.使用 Cloudz 微球、G-Rex6M 和人血小板裂解物无饲养细胞和无血清扩增自然杀伤细胞。
Front Immunol. 2022 Mar 7;13:803380. doi: 10.3389/fimmu.2022.803380. eCollection 2022.
2
Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.无血清培养基配方在饲养细胞刺激自然杀伤细胞扩增中的评价。
Cytotherapy. 2020 Jun;22(6):322-328. doi: 10.1016/j.jcyt.2020.02.002. Epub 2020 Apr 8.
3
Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.表达杀伤细胞免疫球蛋白样受体和 CD94/NKG2A 配体的人工饲养细胞用于扩增具有自我耐受功能的功能性原代自然杀伤细胞。
Cytotherapy. 2020 Jul;22(7):354-368. doi: 10.1016/j.jcyt.2020.02.004. Epub 2020 May 23.
4
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.人自然杀伤细胞制备的优化:全自动分离,使用 IL-21 和自体饲养细胞进行体外扩增的改进,以及生成表达抗 CD123-CAR 的效应细胞。
Hum Gene Ther. 2017 Oct;28(10):897-913. doi: 10.1089/hum.2017.157. Epub 2017 Aug 15.
5
Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.利用自体饲养层和抗CD3抗体扩增自然杀伤细胞用于肝细胞癌的免疫细胞治疗
Asian Pac J Cancer Prev. 2019 Dec 1;20(12):3797-3803. doi: 10.31557/APJCP.2019.20.12.3797.
6
Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers.用健康志愿者的饲养细胞从晚期癌症患者中体外激活和扩增自然杀伤细胞。
Cytotherapy. 2013 Feb;15(2):231-241.e1. doi: 10.1016/j.jcyt.2012.10.019.
7
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.用于癌症犬过继免疫治疗的 PBMC 扩增自然杀伤细胞的临床前评估和首例犬临床试验。
J Immunother Cancer. 2024 Apr 16;12(4):e007963. doi: 10.1136/jitc-2023-007963.
8
Development of Genetically Engineered Feeder Cells for Natural Killer Cell Expansion.用于自然杀伤细胞扩增的基因工程饲养细胞的开发。
Anticancer Res. 2023 Sep;43(9):3897-3904. doi: 10.21873/anticanres.16577.
9
Advances in NK cell production.自然杀伤细胞生产的进展。
Cell Mol Immunol. 2022 Apr;19(4):460-481. doi: 10.1038/s41423-021-00808-3. Epub 2022 Jan 5.
10
Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.使用冷冻保存的辐照饲养细胞进行自然杀伤细胞的体外扩增。
Anticancer Res. 2013 May;33(5):2011-9.

引用本文的文献

1
Scalable production process development for NK cells targeting large-scale expansion.用于靶向大规模扩增的自然杀伤细胞的可扩展生产工艺开发。
Regen Ther. 2025 Aug 5;30:535-543. doi: 10.1016/j.reth.2025.07.014. eCollection 2025 Dec.
2
Characterization of ex vivo expanded natural killer cells for cancer immunotherapy.用于癌症免疫治疗的体外扩增自然杀伤细胞的特性分析
Immunol Cell Biol. 2025 Aug;103(7):664-682. doi: 10.1111/imcb.70038. Epub 2025 Jun 18.
3
Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy.聚焦细胞因子:自然杀伤细胞过继性细胞癌症免疫疗法中的白细胞介素-2和白细胞介素-15

本文引用的文献

1
Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.COVID-19 中的耗竭 NK 细胞和细胞因子风暴:NK 细胞疗法是否可能成为一种治疗选择。
Hum Immunol. 2022 Jan;83(1):86-98. doi: 10.1016/j.humimm.2021.09.004. Epub 2021 Sep 8.
2
Human NK cells: From development to effector functions.人自然杀伤细胞:从发育到效应功能。
Innate Immun. 2021 Apr;27(3):212-229. doi: 10.1177/17534259211001512. Epub 2021 Mar 24.
3
A robust platform for expansion and genome editing of primary human natural killer cells.
Immune Netw. 2025 Apr 9;25(2):e17. doi: 10.4110/in.2025.25.e17. eCollection 2025 Apr.
4
Human platelet lysate as a substitute for serum in natural killer cell generation and expansion.人血小板裂解物作为天然杀伤细胞生成和扩增中血清的替代品。
Life Med. 2023 Mar 13;2(2):lnad011. doi: 10.1093/lifemedi/lnad011. eCollection 2023 Apr.
5
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.嵌合抗原受体自然杀伤(CAR-NK)细胞在癌症治疗中的开发与应用:现状、挑战及新兴治疗进展
Exp Hematol Oncol. 2024 Dec 4;13(1):118. doi: 10.1186/s40164-024-00583-7.
6
Comparison of Natural Killer Cells Differentiated from Various Pluripotent Stem Cells.比较不同多能干细胞分化得到的自然杀伤细胞。
Int J Mol Sci. 2024 Jul 27;25(15):8209. doi: 10.3390/ijms25158209.
7
Scalable process development of NK and CAR-NK expansion in a closed bioreactor.在封闭生物反应器中进行NK和CAR-NK扩增的可扩展工艺开发。
Front Immunol. 2024 Jul 24;15:1412378. doi: 10.3389/fimmu.2024.1412378. eCollection 2024.
8
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.超越 CAR-T:CAR-NK 细胞疗法在哮喘免疫治疗中的兴起。
J Transl Med. 2024 Aug 5;22(1):736. doi: 10.1186/s12967-024-05534-8.
9
Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.用嵌合抗原受体自然杀伤细胞(CAR NK细胞)靶向ROBO1以对抗卵巢癌原发肿瘤细胞和类器官的有前景的方法。
Future Sci OA. 2024 Jul 11;10(1):2340186. doi: 10.2144/fsoa-2023-0135. Epub 2024 Jul 29.
10
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.利用自然杀伤细胞治疗难治性/复发性非霍奇金淋巴瘤:生物学作用、临床试验及未来展望
Biomark Res. 2024 Jul 17;12(1):66. doi: 10.1186/s40364-024-00610-z.
一个用于扩增和基因组编辑原代人自然杀伤细胞的强大平台。
J Exp Med. 2021 Mar 1;218(3). doi: 10.1084/jem.20201529.
4
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.诱导多能干细胞衍生的自然杀伤细胞维持高细胞毒性,并与T细胞和抗程序性死亡蛋白1疗法协同增强体内肿瘤控制。
Sci Transl Med. 2020 Nov 4;12(568). doi: 10.1126/scitranslmed.aaz5618.
5
Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.表达杀伤细胞免疫球蛋白样受体和 CD94/NKG2A 配体的人工饲养细胞用于扩增具有自我耐受功能的功能性原代自然杀伤细胞。
Cytotherapy. 2020 Jul;22(7):354-368. doi: 10.1016/j.jcyt.2020.02.004. Epub 2020 May 23.
6
Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.无血清培养基配方在饲养细胞刺激自然杀伤细胞扩增中的评价。
Cytotherapy. 2020 Jun;22(6):322-328. doi: 10.1016/j.jcyt.2020.02.002. Epub 2020 Apr 8.
7
NK cells mediate clearance of CD8 T cell-resistant tumors in response to STING agonists.NK 细胞通过 STING 激动剂介导清除对 CD8 T 细胞耐药的肿瘤。
Sci Immunol. 2020 Mar 20;5(45). doi: 10.1126/sciimmunol.aaz2738.
8
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.嵌合抗原受体修饰的第三方外周血自然杀伤细胞过继细胞疗法治疗 B 细胞前体急性淋巴细胞白血病的疗效。
Leukemia. 2020 Apr;34(4):1102-1115. doi: 10.1038/s41375-019-0613-7. Epub 2019 Nov 19.
9
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.用于癌症免疫疗法的基因工程化原发性人自然杀伤细胞平台。
Mol Ther. 2020 Jan 8;28(1):52-63. doi: 10.1016/j.ymthe.2019.10.009. Epub 2019 Oct 15.
10
Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells.基于膜结合的 IL-21 的 NK 细胞饲养细胞可驱动 NK 细胞的强大扩增和代谢激活。
Sci Rep. 2019 Oct 17;9(1):14916. doi: 10.1038/s41598-019-51287-6.